Comparing vTv Therapeutics (VTVT) & Its Competitors

vTv Therapeutics (NASDAQ:VTVT) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare vTv Therapeutics to similar businesses based on the strength of its valuation, risk, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares vTv Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
vTv Therapeutics Competitors	-2,372.59%	-220.83%	-15.99%

Analyst Recommendations

This is a breakdown of current ratings and price targets for vTv Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1	1	6	1	2.78
vTv Therapeutics Competitors	7768	13854	25724	1032	2.41

vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 137.08%. As a group, “Pharmaceuticals” companies have a potential upside of 26.48%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than its competitors.

Risk and Volatility

vTv Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ competitors have a beta of -3.79, suggesting that their average share price is 479% less volatile than the S&P 500.

Earnings & Valuation

This table compares vTv Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
vTv Therapeutics	$1.02 million	-$26.97 million	-22.22
vTv Therapeutics Competitors	$3.53 billion	$3.15 billion	547.98

vTv Therapeutics’ competitors have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

vTv Therapeutics beats its competitors on 8 of the 13 factors compared.

About vTv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.